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Introduction: Asthma medication was increasingly used during the second part of the past cen-
tury. There are few detailed data from population studies on use of asthma medication. The
current study aimed to determine the use and determinants of asthma medication in West
Sweden and to assess changes during the last two decades.
Methods: From a random population sample participating in a survey on respiratory symptoms,
2000 individuals were randomly selected for clinical examinations and structured interviews,
1172 participated. All subjects reporting asthma (nZ 1524) were also invited, and 834 partic-
ipated. In total, 964 subjects with asthma participated. Asthma medication use was assessed in
the general population and among two severity categories of asthma: multi-symptom asthma
(MSA) and “other” asthma (having fewer symptoms). Current data, from 2010, was compared
with data from 1992.
Results: Asthma medication was used by 11% of the population, 4.4% used ICS with concurrent
use of LABA, 3.3% used ICS without LABA, while 3.2% only used SABA. Compared with 1992, the
prevalence of asthma medication use had increased with 54%, and use of ICS had increased
from 1.5% to 7.7%.f Gothenburg, Sahlgrenska Academy, Department of Internal Medicine and Clinical Nutrition, Krefting
Gothenburg, Sweden. Tel.: þ46 31 786 6715; fax: þ46 31 786 6730.
u.se (L. Ekerljung).
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686 L. Ekerljung et al.Conclusion: Subjects with MSA reported using asthma medication more frequently and at high-
er doses, and a higher proportion used ICS.A shift in asthma medication use has occurred since
1992, with increased use of ICS and decreased use of SABA only, implying better asthma control
on a population level. Multi-symptom asthma should alert the treating physician to consider
under-medication and/or poor treatment adherence.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
The prevalence of physician-diagnosed asthma has
increased worldwide [1e4], and current Swedish data
suggest the prevalence of asthma to be 7e10% [3,5,6]. This
increase is supported by reports of a high incidence [7,8]
but contrasts to reports of a stable or even decreasing
prevalence of symptoms common in asthma, such as
wheeze and attacks of shortness of breath when compared
with results of studies performed in the 1980s and 1990s
[3,9,10]. Thus there is an on-going debate whether asthma
prevalence is increasing or not [6,11].
In western societies, the prevalence of users of asthma
medication does not fully reflect the true prevalence of
asthma [6,12]. Over the past decades an obvious increase in
asthma medication use has been observed [5,6], partly as a
consequence of an increased awareness of COPD. However,
there are still only few large scale population surveys that
have studied asthma medication use in more detail [12].
Patient reported use of asthma medication contribute to
the validation of estimates of asthma prevalence and, even
more importantly, give important insights into how asthma
care function in society.
To contribute to the identification of asthma with more
significant degrees of severity in population studies we have
proposed the term multi-symptom asthma (MSA) [13]. MSA,
defined as having physician-diagnosed asthma with multiple
symptoms despite reporting use of asthma medication, is
associated with decreased lung function, increased hyper-
reactivity and airway inflammation, exacerbations, emer-
gency visits, night time awakenings [13] and chronic nasal
symptoms [14]. The prevalence of MSA on a population
level is 2% in West Sweden, in agreement with results from
the Swedish capital Stockholm, located in the Eastern part
of Sweden [3,13,14]. Tools for identifying more severe
asthma in a population is important as severe asthma poses
a great burden both on the individual and on society as it is
associated with a decreased quality of life [15], increased
morbidity with need of emergency care and life style re-
strictions [13] and high societal costs [16].
The present study is the first from the West Sweden
Asthma Study to present clinical data from the entire
cohort. The aim was to examine prevalence, distribution
and determinants of asthma medication use in the general
population of West Sweden. Further aims were to compare
use of asthma medication in 1992 and 2010, and to deter-
mine the association between use of asthma medication in
MSA versus other asthma.Methods
Study population and participation
The West Sweden Asthma Study population has previously
been described in detail [6]. In short, in 2008 a validated
questionnaire, including the international GAL2EN-ques-
tionnaire and the OLIN-questionnaire, [5,9,17] was mailed
to 30 000 randomly selected subjects aged 16e75 years,
living in the Swedish region of Va¨stra Go¨taland. The
response rate was 62%. A non-responder study showed high
representativeness of the study area’s population [18]. The
study has been approved by the local Ethics Committee.
The results in the current paper are based on two sub-
samples of responders to the postal questionnaire. From
the responders to the postal questionnaire, 2000 subjects
were randomly selected and invited to clinical examina-
tions, 1172 (59%) participated, 130 of whom reported
asthma (11.1%). In addition, all subjects considered to have
asthma according to the questionnaire, an additional 1524
subjects, were invited, 834 (55%) participated. In total, 964
asthmatics participated in the clinical examinations which
were performed from winter 2009 to winter 2012. The se-
lection procedure is described in Fig. 1.
Changes in asthma medication use were assessed by
comparison with data from the European Community Res-
piratory Health Survey (ECRHS) I performed in 1992 in
Gothenburg [19]. In the comparison only subjects aged
21e46 years, living in the city of Gothenburg were included
(n Z 430) to match the population of ECRHS I.Clinical data
The examinations included an extensive structured inter-
view, including a detailed questionnaire on use of asthma
medication. Other measurements included mainly lung
function measurements, fraction of exhaled NO and skin-
prick tests. The questionnaire on asthma medication use
included questions on type of medication; inhaled corti-
costeroids (ICS only), combination treatment (i.e. ICS and
long-acting beta-2-agonists (LABA), separately or as a
combined inhaler), oral steroids, LABA, short-acting beta-2-
agonists, (SABA), leukotriene antagonists and bronchodila-
tors through nebuliser. For ICS, the subjects stated the
name of the medication, and what daily dose they used.
Questions on frequency of use included 6 options; 1) never,
2) a few times/year, 3) a few times/month, 4) no more than
Figure 1 Study set up. The study population was based on a questionnaire survey from which a random and an asthmatic sample
were invited to clinical examinations.
Asthma medication use in a general population 687twice a week, 5) at least 3 times a week and 6) daily or
almost daily. In the analysis the options were condensed
into three categories, 1 and 2 were considered as “never”,
3 and 4 as “occasionally” and 5 and 6 as “most days”. Dose
of ICS is given as beclomethasone dipropionate (BDP)
equipotent doses and grouped into low (200e500 mg BDP),
medium (>500e1000 mg BDP) and high (>1000 mg BDP) daily
doses.
Definitions of asthma
Based on self-administrated questionnaire reports in 2008,
subjects were considered as asthmatics if they reported
physician-diagnosed asthma, or reported ever asthma with
medication use, wheeze, or attacks of shortness of breath
during the last 12 months. MSA was defined as physician-
diagnosed asthma and asthma medication and attacks of
shortness of breath and recurrent wheeze and at least one
out of dyspnoea, breathlessness at exertion, breathless-
ness in cold conditions, and breathlessness at exertion in
cold conditions. Asthmatic subjects not reporting MSA are
referred to as having other asthma (OA).
Analyses
Statistical analyses were performed using SPSS version
18.0. Comparisons of proportions were tested using Fisch-
er’s exact test, and the Mantel-Haenszel’s test for trend
was used when appropriate. T-tests were used to compare
means between two groups. A p-value of <0.05 wasregarded as statistically significant. Adjusted logistic
regression analyses were performed to determine risk fac-
tors, presented as odds ratios (OR) with 95% confidence
intervals (95% CI).
Calculations of prevalence in the population and
possible determinants were based only on the random
sample, representing the population of Va¨stra Go¨taland.
Medication use among subjects with asthma was investi-
gated using data both from the random sample and from
the enriched asthma sample. A sensitivity analysis was
performed to compare subjects living on Hisingen to all
subjects living in Gothenburg in regards to symptoms and
risk factors by using Fischer’s exact test. The sensitivity
analysis revealed no significant differences between sub-
ject living on Hisingen and subjects from the whole Goth-
enburg area. An agreement analysis using data collected
from the drug registry maintained by the National Board of
Health and Welfare was performed on a subsample. Pre-
scription refill data was collected between 2008-01-01 and
2012-06-30, and the refill prior to the visit to our clinic was
used for the agreement analysis using kappa-statistic and
absolute agreement.
Results
Prevalence of medication use in the population
The prevalence of asthma medication use was 11% in the
clinically examined random sample (n Z 1172). The most
common asthma medication was SABA, which was used by
688 L. Ekerljung et al.8.3% of the population, followed by a combination treat-
ment, i.e. ICS and LABA, (4.4%) and ICS only (3.3%). The
majority of SABA users (61%) used SABA in combination with
ICS.
Among all users of asthma medication, 38% used ICS only
with or without additional SABA or LABA, while 30% had a
combined inhaler, with or without additional SABA (Fig. 2).
Among users of ICS, 48% used ICS only while 52% used ICS in
combination with LABA. A fixed combination inhaler was
used by 85% of subjects on combination treatments. SABA
only was used by 27% while 6.6% used LABA only.
Change in asthma medication use 1992e2010
Comparison with ECRHS from 1992 showed an increased use
of asthma medication in the Gothenburg population aged
21e46, from 7.8% to 12%, p Z 0.02 (Fig. 3). The increase
mainly consisted of an increased use of ICS from 1.5% to
7.7%, p < 0.001, while the proportion who used SABA did
not change significantly. The introduction of LABA during
the time between the studies was clearly visible, with 4.4%
of the population of young adults using LABA in 2010 while
there were no LABA users in 1992. Among asthmatics there
was a strong decrease in the prevalence of using only SABA
with no additional medications, from 47% to 23%, p < 0.001,
in this younger population.
Prevalence of medication use among asthmatics
Of the subjects with asthma (nZ 964), 66% were currently
using asthma medication. ICS only were used by 20% and
combination treatment was used by 24%. The prevalence of
SABA use without concomitant use of ICS was 17% (Fig. 4).
Oral corticosteroids were used occasionally by 6.2%, and
only 0.3% used oral corticosteroids regularly. Among users
of LABA, 16% did not also use corticosteroids. Leukotriene
antagonists were used by 2% of the asthmatics, 29% of
which did not use ICS. Use of any asthma medication was
more common in women than men (Table 1). Use of ICS andFigure 2 Distribution (per cent) of asthma medication use
among subjects with asthma in the random sample. ICS e
inhaled corticosteroids, SABA e short-acting b2-agonists, LABA
e long-acting b2-agonists, Combination treatment e ICS and
long-acting b2-agonists as a combined inhaler.combination treatment, respectively, increased by age. Use
of any asthma medication and SABA was higher among
subjects with allergic rhinitis.
Medication use in multi-symptom asthma and other
asthma
The prevalence of use of medication for asthma was 91%
among MSA (n Z 201) and 59% among OA (n Z 763). Sixty-
eight per cent of subjects with MSA and 40% of subjects
with OA used ICS (p < 0.001, Fig. 4). Of subjects with MSA
42% used a combination treatment, and of these, 88% used
a combination inhaler and the remaining used LABA and ICS
separately. Among subjects with OA only 22% used a com-
bination treatment including ICS. Among subjects not using
ICS (32% in MSA and 54% in OA), the prevalence of SABA use
was 64% in the MSA group and 29% in the OA group
(p < 0.001, Fig. 4). Two-thirds of oral steroid users were
found in the MSA group, despite MSA constituting only 21%
of the whole population of asthmatics.
With increasing age, all groups reported an increased
prevalence of use of ICS and combination treatment. The
prevalence of SABA use decreased with increasing age
(Table 1).
In order to validate the self-reported use of maintenance
treatment an agreement analysis using registry data was
performed. A randomly selected subsample of 74 subjects
revealed an absolute agreement of 82% for ICS and 91% for
combination treatment, with kappa-values above 0.6.
Frequency and dosages of medication
Of subjects with MSA, 34% used combination treatment
most days versus 15% for OA (p < 0.001). The corresponding
figures for use of ICS most days were 49% and 24%, p < 0.001
(Table 2). Subjects with MSA used higher doses of ICS
compared with OA. High dose, i.e. >1000 mg, was used by
6.5% and 1.9% of MSA and OA, respectively (p < 0.001).
Medium dose was used by 45% and 24% and low dose by 12%
and 9.8%. Using ICS most days increased with age both
among subjects with MSA and OA but was highly more
prevalent among MSA in all age groups.
Determinants of medication use
In an adjusted logistic regression model including age, BMI,
population density gradient, smoking status, chronic
rhinitis and allergic rhinitis the same pattern appeared for
all investigated medication variables: any asthma medica-
tion; any inhaled corticosteroid; combination treatment;
and high dose of any inhaled corticosteroid (Table 3).
Allergic rhinitis, chronic rhinitis and having a BMI 30 were
stable risk factors for all medication variables. For use of
ICS also increasing age was a risk factor.
Discussion
The study is the first from the West Sweden Asthma Study to
present data from the clinical phase. The study reports an
asthma medication use of 11% in a randomly selected
Figure 3 Prevalence of asthma medication use in the population of Gothenburg aged 21e46 years in 1992 and 2010. p-Value e
Fischer’s exact test: *>0.05, ***<0.001, ns e non significant, N/A e not possible to calculate. #LABA in combination with ICS and
taken separately. The prevalence included both regular and occasional use. WSAS eWest Sweden Asthma Study. ECRHS e European
Community Respiratory Health Survey.
Asthma medication use in a general population 689population of adults. Of subjects with asthma, two thirds
used asthma medications, the most common being ICS and
SABA, and SABA alone was only used by a one fourth of
these subjects. Use of ICS increased with age in all asthma
groups, while the use of SABA decreased with age. The use
of leukotriene antagonists was low. Between 1992 and 2010
asthma medication use had increased by 54%. The increase
probably reflects a combination of the increase in preva-
lence of physician-diagnosed asthma during the time periodFigure 4 Prevalence of asthma medication use among subjects w
exact test: *>0.05, **<0.01, ***<0.001, ns e non significant. The p[3,6] as well as the increased use of inhaled corticosteroids
[20]. An increased observance of COPD has probably also
contributed to the increase in asthma medication use. A
major shift in asthma treatment had occurred between
1992 and 2010, with considerably more subjects in 2010
using ICS and fewer using only SABA. In addition, the
changed prescriptions options and regimens could be seen
in the switch from oral to inhaled SABA, and the introduc-
tion of LABA. During the time period use of evidence basedith asthma, divided by degree of severity. p-Value e Fischer’s
revalence included both regular and occasional use.
Table 1 Prevalence (%) of current use of asthma medication by gender, age group, smoking status and presence of allergic and
chronic rhinitis within multi-symptom asthma. Significant p-vales, and associated prevalence are depicted in bold.
Gender Allergic rhinitis Chronic rhinitis
Male (%) Female (%) p-Value No (%) Yes (%) p-Value No (%) Yes (%) p-Value
Any asthma medication
All asthma 61.0 69.1 0.011 59.1 70.0 0.001 63.1 69.3 0.052
Multi-symptom asthma 92.6 90.2 0.795 88.9 92.2 0.449 93.2 89.3 0.457
Other asthma 54.6 62.3 0.037 52.1 63.6 0.002 57.5 61.1 0.356
Inhaled corticosteroids
All asthma 40.0 50.6 0.001 47.2 45.3 0.595 44.0 49.1 0.128
Multi-symptom asthma 64.7 69.7 0.523 72.2 65.6 0.349 68.2 67.9 1.000
Other asthma 35.0 44.5 0.009 41.4 39.4 0.597 39.5 41.5 0.643
Inhaled corticosteroids only
All asthma 17.0 22.5 0.041 18.1 21.5 0.216 20.3 19.9 0.934
Multi-symptom asthma 19.1 30.3 0.094 23.6 28.1 0.510 30.7 23.2 0.261
Other asthma 16.6 20.0 0.257 16.8 19.6 0.389 18.4 18.5 1.000
Combination treatmentb
All asthma 22.7 28.2 0.061 29.1 23.6 0.059 23.5 29.2 0.059
Multi-symptom asthma 45.6 39.4 0.450 48.6 37.5 0.137 37.5 44.6 0.316
Other asthma 18.1 24.6 0.033 24.6 19.6 0.105 20.9 22.9 0.521
Short acting b2-agonistsc
All asthma 19.0 16.2 0.262 10.5 22.0 0.000 16.9 18.1 0.664
Multi-symptom asthma 25.0 17.4 0.263 13.9 23.4 0.140 21.6 18.8 0.722
Other asthma 17.8 15.8 0.491 9.7 21.6 0.000 16.1 17.8 0.543
Age group Smoking status
17e30
(%)
31e45
(%)
46e60
(%)
61e78
(%)
p-Valuea Non-smoker
(%)
Ex-smokers
(%)
Smokers
(%)
p-Valuea
Any asthma medication
All asthma 62.3 63.9 68.3 67.5 0.167 66.1 65.9 62.5 0.550
Multi-symptom asthma 86.5 86.3 96.7 92.3 0.135 89.5 92.2 92.7 0.498
Other asthma 56.2 59.0 60.1 59.4 0.551 60.6 59.8 45.1 0.059
Inhaled corticosteroids
All asthma 36.1 40.7 50.4 56.6 0.000 44.2 48.2 48.2 0.266
Multi-symptom asthma 56.8 58.8 68.3 84.6 0.002 63.2 75.0 68.3 0.360
Other asthma 30.8 36.8 45.2 47.5 0.001 39.7 42.0 36.6 0.971
Inhaled corticosteroids only
All asthma 14.8 20.4 23.5 20.3 0.130 20.5 20.6 17.9 0.640
Multi-symptom asthma 24.3 19.6 35.0 25.0 0.512 23.2 28.1 31.7 0.276
Other asthma 12.3 20.5 20.2 18.8 0.218 19.8 18.8 9.9 0.103
Combination treatmentb
All asthma 20.8 20.0 26.9 36.8 0.000 23.3 27.6 31.3 0.048
Multi-symptom asthma 32.4 37.3 33.3 61.5 0.009 38.9 46.9 39.0 0.796
Other asthma 17.8 16.2 25.0 28.8 0.002 19.6 23.2 26.8 0.116
Short acting b2-agonistsc
All asthma 24.6 21.1 16.0 8.0 0.000 19.9 15.9 10.7 0.014
Multi-symptom asthma 29.7 23.5 23.3 5.8 0.006 23.2 15.6 19.5 0.469
Other asthma 23.3 20.5 13.9 8.8 0.000 19.1 15.9 5.6 0.009
a p-Value test for trend.
b Inhaled corticosteroids and long acting b2-agonists.
c Without use of steroids.
690 L. Ekerljung et al.guidelines for the treatment of asthma was implemented
and results suggests more appropriate treatment regimens
in 2010 and, possibly, also better asthma control.
Severe asthma is difficult to define in epidemiology, and
the prevalence in different populations depends on the
definitions used. Most definitions are mainly based on
symptom severity despite the highest level of treatment orrequired need of asthma medication to achieve controlled
disease [4,21e24]. In a recent publication, the WHO defines
severe asthma as “uncontrolled asthma which can result in
risk of frequent severe exacerbations and/or adverse re-
actions to medications and/or chronic morbidity” [25], a
definition that does not include use of asthma medication.
We have chosen a wide definition as a proxy for severe
Table 2 Frequency of medication use among all asthma, multi-symptom asthma and other asthma. Significant p-vales are
depicted in bold.
All asthma (%) Multi-symptom
asthma (%)
Other
asthma (%)
Test for
trendc
Inhaled corticosteroids Never 54.2 32.0 60.2 <0.001
Occasionally 16.4 19.5 15.5
Most days 29.4 48.5 24.3
Inhaled corticosteroids, only Never 75.8 68.0 77.9 0.003
Occasionally 10.1 12.5 9.5
Most days 14.0 19.5 12.6
Combination treatmenta Never 74.4 58.5 78.6 <0.001
Occasionally 6.4 7.5 6.1
Most days 19.2 34.0 15.2
Oral steroids Never 93.5 87.5 95.1 <0.001
Occasionally 6.2 12.0 4.7
Most days 0.3 0.5 0.3
Short-acting b2-agonist Never 49.4 27.5 55.2 <0.001
Occasionally 32.6 38.5 31.0
Most days 18.0 34.0 13.8
Short-acting b2-agonistb Never 82.6 80.0 83.3 0.040
Occasionally 13.6 12.5 13.9
Most days 3.8 7.5 2.8
Bronchodilator through
nebuliser
Never 97.9 94.0 98.9 <0.001
Occasionally 1.6 4.5 0.8
Most days 0.5 1.5 0.3
a Inhaled corticosteroids and long acting b2-agonists.
b Without use of steroids.
c Multi-symptom asthma versus other asthma.
Asthma medication use in a general population 691asthma, aimed at identifying a more severe asthma in
epidemiological studies and to give guidance to treatment
in health care. The subjects meeting our MSA criteria report
more symptoms, have a lower lung function and more
airway inflammation [13]. While MSA subjects may well be
under-treated, our findings underline that MSA reflects a
high symptom burden despite higher use of asthmaTable 3 Risk factors (odds ratios (95% confidence intervals)) a
regression. Significant risk factors are depicted in bold.
Any asthma
medication
Any in
cortic
Age 31e45 0.99 (0.73e1.35) 1.14 (
46e60 0.96 (0.70e1.33) 1.32 (
61e78 0.89 (0.64e1.25) 1.46 (
BMI <20 0.84 (0.49e1.45) 1.10 (
25e29 1.17 (0.92e1.48) 1.15 (
30 1.69 (1.28e2.23) 1.64 (
Population
density
500e2000 0.77 (0.46e1.30) 0.70 (
2000e10 000 1.05 (0.68e1.62) 1.43 (
>10 000 0.76 (0.55e1.05) 0.88 (
Smoking Former 0.98 (0.78e1.23) 0.96 (
Current 0.95 (0.69e1.31) 1.07 (
Chronic rhinitis Yes 1.79 (1.45e2.21) 1.76 (
Allergic rhinitis Yes 3.28 (2.67e4.01) 2.14 (
Reference categories were: being aged 17e30, having a BMI of 20e
rhinitis and not having allergic rhinitis, respectively.medication compared to other asthmatics. MSA could fit in
the WHO severe asthma definition of “difficult-to treat”
severe asthma [25], as multiple symptoms can be due to
adherence issues.
Until now there has been no data on medication use in
more severe asthma from population studies and we hope
that our data will contribute to the understanding of thisssociated with use of asthma medication. Adjusted logistic
haled
osteroids
Combination
treatment
High dose any inhaled
corticosteroids
0.81e1.62) 0.92 (0.59e1.43) 1.28 (0.85e1.94)
0.92e1.88) 1.13 (0.72e1.75) 1.27 (0.83e1.95)
1.01e2.11) 1.57 (1.01e2.45) 1.44 (0.93e2.24)
0.62e1.98) 1.50 (0.78e2.88) 1.16 (0.59e2.27)
0.89e1.49) 0.94 (0.68e1.31) 1.14 (0.84e1.56)
1.22e2.20) 1.50 (1.05e2.14) 1.73 (1.22e2.45)
0.39e1.26) 0.90 (0.44e1.86) 0.61 (0.30e1.24)
0.91e2.25) 1.58 (0.90e2.79) 1.23 (0.72e2.10)
0.62e1.25) 0.99 (0.63e1.56) 0.83 (0.55e1.26)
0.75e1.22) 1.03 (0.76e1.40) 1.02 (0.76e1.36)
0.76e1.51) 1.27 (0.84e1.92) 1.10 (0.73e1.65)
1.41e2.21) 1.97 (1.49e2.60) 1.76 (1.35e2.30)
1.71e2.67) 1.59 (1.20e2.09) 2.36 (1.81e3.07)
24, non-smoking, a population density <500, not having chronic
692 L. Ekerljung et al.issue. Worldwide many subjects fall short of treatment
goals [26,27]. Despite guideline recommendations, the
limited reviews available suggests that control of persistent
asthma remains poor [28] with combination treatment
being regarded as the most effective [29]. In view of this it
is discouraging that only 44% of subjects with MSA and 22%
of subjects with OA report use of a combination treatment,
however, this is in line with other studies [28,30].
Those classified as having MSA used their medication
more frequently and in higher doses than those classified as
having OA. Further, maintenance treatment was consider-
ably more common among those with MSA, reflecting cur-
rent guidelines where subjects with persistent asthma
should not only use relief medication. In contrast to current
guidelines, 29% of users of LABA with MSA and 11% of users
of LABA with OA did not concomitantly use ICS.
The prevalence of asthma medication use varies largely
in Europe. Data from the 1992 ECHRS study report preva-
lence of asthma medication ranging from 1% to 9% [31]. Use
of broncho-pulmonary drugs was reported by 5% in a gen-
eral population in Italy in early 1990s, lower than in the
ECHRS study group that was used for comparison in our
study [32]. The use of ICS and LABA only found in the cur-
rent study is slightly higher than in a clinical sample
investigated in early 2000s [28].
Issues of non-adherence are well recognised in asthma
and low adherence is associated with poor asthma control
and an increased risk of exacerbations [33,34]. We estimate
that in our study at least 30% of MSA can be due to low
adherence or under-treatment, as they do not have a
maintenance treatment, or use it irregularly. This is in line
with another study where 35% of asthmatics had non-
adherence as the main cause of difficult-to-treat asthma
[35].
The identified risk factors, with the exception of old
age, reflects, as expected, risk factors previously associ-
ated with asthma [8,13]. It has previously been shown that
concomitant rhinitis increases the burden of asthma results
in a lower level of asthma control [36]. The association
between old age and ICS could reflect a lower adherence to
maintenance treatment among younger subjects [37].
Smokers used combination treatment to a greater extent
than ex-smokers and non-smokers, possibly reflecting
COPD, especially as these subjects were older.
A strength of the current study is the large study popu-
lation drawn from the general population which results in
high degree of representativeness of the population in the
studied region [18]. Some of the subjects regarded as
asthmatics might have COPD. Most asthmatics in the cur-
rent study had an onset of disease in young adulthood or
earlier but might have developed a combination of asthma
and COPD. The main weakness of the study is the lack of
objective measurements of medication use. However, we
suggest that the results are reasonably accurate as many
subjects admit non-adherence. An agreement analysis
revealed high absolute agreement for ICS and combination
treatment, with kappa-vales above 0.6, suggesting sub-
stantial agreement. However, an additional aim for the
future should be to investigate adherence by using data
from the prescription refill registry in a larger sample. The
response rates of 59% and 55% in the random and asthmatic
sample respectively, while comparable to many otherinternational studies, instigated a sensitivity analysis. This
analysis showed no differences in gender, smoking or re-
ported use of asthma medication between participants and
non-participants. However, participants reported some-
what more ever and physician-diagnosed asthma, any
wheeze and allergic rhinitis. We do not believe these dif-
ferences had any major influence on the results.
In conclusion, an increase in asthma medication use of
54% from 1992 could be observed. A shift in asthma medi-
cation use from 1992, with an increased in the use of ste-
roids and a decreased in the use of SABA was also found.
Moreover, it demonstrates that the presence of multiple
asthma symptoms in a patient should alert the treating
physician to the possibilities of under-medication and poor
adherence to the treatment regimen.
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